Clinical Trial Update: POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating ESK-001 for active noninfectious uveitis (intermediate, posterior, or panuveitis) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermediate Uveitis
• Noninfectious Uveitis
• Panuveitis
• Posterior Uveitis

Drugs mentioned

• ESK-001

Snippet

Sponsor: Alumis Inc | Conditions: Uveitis Posterior Non-Infectious, Uveitis, Intermediate | Phase 2 | Status: TERMINATED